1. Introduction {#sec0005}
===============

A disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) proteases are non-membrane bound enzymes that are able to interact with and degrade components of the extracellular matrix (ECM), such as pro-collagen and hyalectans ([@bib0140; @bib0060; @bib0130]). Of the ADAMTS proteases identified to date, ADAMTS-1 and ADAMTS-4 are the most abundant and consequently have been the subject of the majority of research on these enzymes ([@bib0140; @bib0060]). There has been much focus on the ability of ADAMTS proteases to cleave aggrecan, a proteoglycan present in articular cartilage ([@bib0140; @bib0115; @bib0160]). Cleavage of aggrecan in human cartilage contributes to the pathophysiology of osteoarthritis and rheumatoid arthritis and a role for ADAMTS-4 in this process has been defined ([@bib0140; @bib0115; @bib0160]).

A possible role for the ADAMTS proteases as contributors to inflammation and atherosclerosis has only recently come to light ([@bib0140]). Atherosclerosis, the primary cause of coronary heart disease, is an inflammatory disorder orchestrated by the action of cytokines. The latter stages of this disease are associated with the migration and the proliferation of vascular smooth muscle cells (VSMCs), which leads to the production of the extracellular matrix and the formation of a fibrous cap in the atherosclerotic plaque ([@bib0015]). The balance between the synthesis and the degradation of the ECM by matrix metalloproteinases (MMPs) and other proteases determines the susceptibility of the plaque to rupture and subsequent thrombosis and myocardial infarction ([@bib0085; @bib0095]).

The ADAMTS proteases were first associated with inflammation when it was shown that administration of lipopolysaccharide (LPS) *in vivo* could enhance ADAMTS-1 expression in the heart and in the kidneys ([@bib0080]). ADAMTS-1, -4 and -8 have been found to be present within atherosclerotic lesions and mice overexpressing ADAMTS-1 crossed with ApoE-deficient mice, an animal model for atherosclerosis, showed increased thickening of the arterial intima ([@bib0205; @bib0065; @bib0195]). ADAMTS-4 is predominantly associated with macrophages of atherosclerotic lesions and its expression is increased following both monocyte--macrophage differentiation and during development of atherosclerosis in a mouse model system ([@bib0195]). The ability of the ADAMTS proteases to cleave proteoglycans is likely to be central to any proposed role in atherosclerosis. Both ADAMTS-1 and -4 are able to cleave versican, a proteoglycan similar in structure to aggrecan but predominantly expressed in the vasculature ([@bib0145]). Versican expression is upregulated in vascular disease, accumulates in atherosclerotic plaques ([@bib0210]) and can be cleaved by ADAMTS-1 and ADAMTS-4 at specific Glu-Ala bonds ([@bib0145]). It has also been shown that in the human aorta, versican fragments can be generated by ADAMTS-1 and ADAMTS-4 digestion of intact human versican ([@bib0145]).

Very few studies have investigated the regulation of ADAMTS protease expression in macrophages and further studies are necessary especially as ADAMTS-4 has been found to colocalize with macrophages of atherosclerotic lesions ([@bib0195]). To our knowledge only one study has been carried out that investigated the expression of ADAMTS proteases in response to cytokines in human macrophages and this demonstrated that ADAMTS-4 expression was up-regulated by the pro-inflammatory cytokines interferon-γ (IFN-γ) and tumour necrosis factor-α ([@bib0195]).

TGF-β is a major anti-atherogenic cytokine and inhibition of its actions, using neutralising antibodies or expression of a dominant negative receptor, has been found to accelerate the development of atherosclerosis in mouse models of this disease ([@bib0150]). The cytokine inhibits foam cell formation and an inverse relationship has been identified between circulating levels of TGF-β and the development of atherosclerosis ([@bib0150]). In addition, regions in the aorta with low TGF-β expression have a high probability of developing atherosclerosis ([@bib0150]). TGF-β is also known to inhibit the expression of MMPs, which decrease plaque stability via thinning of the fibrous plaque through cleavage of collagens, elastins and other proteoglycans in the ECM ([@bib0040; @bib0150; @bib0120]). In light of such a potent anti-atherogenic role of TGF-β, we examined its action on ADAMTS-4 expression in human macrophages with a view to further investigating the molecular mechanisms underlying such regulation. We show here that TGF-β down-regulates ADAMTS-4 expression at the level of mRNA, protein and promoter activity. In addition, our studies demonstrate a critical role for Smads, p38 mitogen-activated protein kinase (MAPK) and c-Jun in the regulation of ADAMTS-4 by TGF-β.

2. Materials and methods {#sec0010}
========================

2.1. Reagents {#sec0015}
-------------

The human monocytic leukaemia THP-1 cell line and the human hepatoma Hep3B cell line were obtained from the European Collection of Animal Cell Cultures (ECACC). Human recombinant TGF-β1 was from Peprotech, validated Smad-2, c-Jun and extracellular signal-regulated kinase (ERK) 1/2 small interfering RNA (siRNA) was from Qiagen and validated Smad-3 and p38 MAPK siRNA was from Invitrogen. Antibodies were from Affinity Bioreagents (ADAMTS-4), Cell Signaling Technology (Smad2/3, p38MAPK, ERK1/2), Santa Cruz Biotechnology (c-Jun) and Sigma (β-actin). Superfect™ transfection reagent was from Qiagen and INTERFERin™ from Polyplus Transfection.

2.2. Cell culture {#sec0020}
-----------------

The cell lines were maintained in either DMEM (Hep3B) or RPMI-1640 (THP-1) supplemented with 10% (v/v) heat-inactivated fetal calf serum, 100 U/ml penicillin and 100 μg/ml Streptomycin. The cultures were maintained in a humidified atmosphere at 37 °C containing 5% (v/v) CO~2~. THP-1 monocytes were differentiated into macrophages using 0.16 μg/ml phorbol 12-myristate 13-acetate (PMA). For human monocyte-derived macrophages (HMDMs), Ficoll--Hypaque purification was used to isolate the cells from buffy coats ([@bib0100; @bib0105; @bib0090]). Blood layered over Lymphoprep™ (Nycomed Pharmaceuticals) in Accuspin™ tubes (Sigma) was centrifuged and platelets removed from the mononuclear cell interface by washing several times with PBS, containing 0.4% (v/v) tri-sodium citrate. Monocytes were plated out in RPMI-1640 supplemented as described above, except containing 5% (v/v) fetal calf serum, and left to differentiate into macrophages for 7 days.

2.3. Transfection of siRNA {#sec0025}
--------------------------

THP-1 monocytes were transfected with 7.5 nM siRNA using INTERFERin™ essentially as described by the manufacturer (PolyPlus Transfection). The cells were then incubated for 24 h before differentiation into macrophages using PMA as described above and subsequent treatment with TGF-β (30 ng/ml). Gene silencing was measured 48 h after transfection by Western blot analysis.

2.4. Real-time quantitative PCR (RT-qPCR) {#sec0030}
-----------------------------------------

RT-qPCR was carried out using primers against ADAMTS-4 or the ribosomal protein L13A (RPL13A) or the glyceraldehyde 3-dehydrogenase (GAPDH) control genes and the SYBR^®^ Green JumpStart™ *Taq* ReadyMix™ (Sigma) on a DNA Engine Opticon 2^®^ real-time PCR detection system (MJ Research). The sequences of the primers were 5′-GGGATAGTGACCACATTGTT-3′ and 5′-AGGCACTGGGCTACTACTAT-3′ for ADAMTS-4; 5′-CCTGGAGGAGAAGAGGAAAGAGA-3′ and 5′-TTGAGGACCTCTGTGTATTTGTCAA-3′ for RPL13A; and 5′-GAAGGTGAAGGTCGGAGTC-3′ and 5′-GAAGATGGTGATGGGATTTC-3′ for GAPDH. For each transcript a standard curve was constructed using a recombinant pGEM-T plasmid containing the PCR product generated for each specific set of primers. A melting curve was constructed to verify single product amplification and the comparative Ct method was used for analysis and normalisation to the control transcript levels.

2.5. Transient transfection assays {#sec0035}
----------------------------------

Hep3B and U937 cells were transfected using Superfect™. Transfection of U937 cells was carried out as previously described ([@bib0050; @bib0055]). For Hep3B, the cells were subcultured at a ratio of 1:6 into 12-well plates 24 h prior to transfection and medium replaced with fresh DMEM before transfection. The DNA:Superfect™ mix was prepared according to the manufacturer\'s instructions (Qiagen) in 50 μl medium containing no antibiotics or serum. The mixture was incubated at room temperature for 10 min and then diluted with DMEM medium before being added to the cells. The cells were then left for 30 min and then treated with vehicle or TGF-β (30 ng/ml) for 24 h. The cells were then harvested using 1× passive lysis buffer (Promega) and the luciferase activity measured using a commercially available kit (Promega). The luciferase activity was normalised to total protein levels as determined using the micro BCA protein assay kit according to the manufacturer\'s instructions (Pierce).

2.6. Western blot analysis {#sec0040}
--------------------------

Samples were prepared in Laemmli buffer and size-fractionated under reducing conditions using 10% SDS-polyacrylamide gels and transferred to a PVDF membrane (Millipore) by Western blotting ([@bib0005]). Incubation with primary and secondary antibodies and chemiluminescent detection was carried out as described previously ([@bib0005]). Samples were subjected to electrophoresis alongside comparative molecular weight markers (GE Healthcare) to determine the size of the protein product. Membranes were developed using chemiluminescence detection reagents (GE Healthcare) and Kodak XAR sensitive film (Sigma).

2.7. Statistical analysis of data {#sec0045}
---------------------------------

Statistical comparisons of data were carried out using Student\'s *t* test with *P* \< 0.05 considered statistically significant. Semi-quantitative, densitometric analysis of Western blot signals was performed using the GeneTools software (GRI).

3. Results {#sec0050}
==========

3.1. TGF-β inhibits ADAMTS-4 expression at the mRNA and protein level in THP-1 macrophages and HMDMs {#sec0055}
----------------------------------------------------------------------------------------------------

The action of TGF-β on the expression of ADAMTS-4 in human macrophages has not been determined and was therefore investigated. The THP-1 monocytic cell line, which can be differentiated into macrophages using PMA, is used extensively to investigate macrophage gene expression in relation to atherosclerosis because of demonstrated conservation of responses with primary macrophage cultures, in particular gene regulation by cytokines ([@bib0010; @bib0100; @bib0105; @bib0090]).

Our previous studies on the TGF-β-mediated activation of apolipoprotein E expression showed maximal response at 24 h with 30 ng/ml of the cytokine ([@bib0155]). We therefore carried out dose--response RT-qPCR experiments on ADAMTS-4 using the 24 h incubation period. As shown in [Fig. 1](#fig0005){ref-type="fig"}A, a marked inhibition of ADAMTS-4 mRNA expression was observed with 2 ng/ml TGF-β with maximal suppression using 30 ng/ml of this cytokine. Further time course experiments using 30 ng/ml of the cytokine showed that ADAMTS-4 mRNA expression was down-regulated by TGF-β within 1 h of treatment and this response was sustained over the 24 h time period. Subsequent experiments were carried out using 30 ng/ml of TGF-β for an incubation period of 24 h, unless otherwise stated.

To determine whether this down-regulation was accompanied by a corresponding change in the level of protein, the expression of ADAMTS-4 was investigated using Western blot analysis. Preliminary experiments showed that the expression of ADAMTS-4 protein was decreased with delayed kinetics compared to RNA (data not shown) so longer incubation periods were used for Western blot analysis. [Fig. 2](#fig0010){ref-type="fig"}A shows that ADAMTS-4 protein expression was significantly down-regulated in THP-1 macrophages by TGF-β treatment. In the light of these results and to confirm that the TGF-β-mediated decrease in ADAMTS-4 expression was not peculiar to the THP-1 cell line, we decided to carry out representative experiments in primary cultures of HMDMs. For this, the action of TGF-β on ADAMTS-4 protein expression was determined. [Fig. 2](#fig0010){ref-type="fig"}B shows that protein expression of ADAMTS-4 was down-regulated by TGF-β in these primary cultures.

3.2. TGF-β inhibits ADAMTS-4 promoter activity {#sec0060}
----------------------------------------------

In order to investigate whether the action of TGF-β was mediated, at least in part, at the transcriptional level through the regulation of promoter activity, the effect of this cytokine on ADAMTS-4 promoter activity in transfected cells was determined. Because of difficulties in transfecting the THP-1 cell line with exogenous DNA, most experiments were carried out using the human hepatoma Hep3B cell line. These cells are used extensively to investigate the regulation of gene expression by cytokines in relation to inflammation (acute-phase response) with demonstrated conservation of responses to primary cultures ([@bib0025; @bib0030] and references therein). Western blot analysis showed that TGF-β also inhibits ADAMTS-4 expression in these cells ([Fig. 3](#fig0015){ref-type="fig"}), thereby showing that the response was also conserved in hepatocytes. The 48 h time point was chosen for experiments in these cells as it corresponded to maximal decrease in ADAMTS-4 expression as identified by preliminary time course analysis (data not shown).

We employed four promoter deletion constructs linked to the luciferase gene: −726/+406 (p1132-LUC); −383/+406 (p789-LUC); −100/+406 (p506-LUC); and +11/+406 (p396-LUC) ([Fig. 4](#fig0020){ref-type="fig"}A) ([@bib0110]). A TGF-β-mediated decrease in promoter activity was obtained with the p1132-LUC, p789-LUC and p-506-LUC constructs but not with the p-396-LUC construct ([Fig. 4](#fig0020){ref-type="fig"}B). This suggests that the minimal TGF-β response elements reside between the −100 and the +10 region. Similar results were obtained when representative experiments were carried out using human U937 macrophages ([Fig. 4](#fig0020){ref-type="fig"}C) \[the luciferase reporter gene activity from the +11/+406 (p396-LUC) construct in these cells was negligible and was therefore not included for further analysis\].

3.3. The action of TGF-β on ADAMTS-4 expression requires Smads, p38 MAPK and c-Jun {#sec0065}
----------------------------------------------------------------------------------

TGF-β mediates many of its actions through the classical Smad signalling pathway with the three MAPK pathways \[ERK, c-Jun N-terminal kinase (JNK) and p38 MAPK\] required in the regulation of certain genes ([@bib0165]). Most of these studies have been carried out in relation to the TGF-β-mediated induction of gene expression and very little is currently understood in relation to the inhibition of gene expression. We therefore analysed whether the Smad or MAPK pathways had any role in the regulation of ADAMTS-4 expression by this cytokine. This was investigated using siRNA-mediated RNA interference assays and RT-qPCR analysis. As in a number of previous studies, GAPDH siRNA was used as a control ([@bib0005]) and this had no effect on the TGF-β-mediated inhibition of ADAMTS-4 expression ([Fig. 5](#fig0025){ref-type="fig"}). Knockdown of Smad-2 plus 3, ERK 1/2, c-Jun, a key downstream target of the JNK pathway, and p38 MAPK was achieved using commercially validated siRNA sequences and relative expression of each protein following siRNA-mediated knockdown was confirmed in THP-1 macrophages by Western blot analysis ([Fig. 5](#fig0025){ref-type="fig"}A). The TGF-β-mediated inhibition of ADAMTS-4 expression was attenuated by knockdown of Smad-2 plus -3 ([Fig. 5](#fig0025){ref-type="fig"}B). In addition, the TGF-β-mediated inhibition of ADAMTS-4 expression was attenuated by knockdown of c-Jun and p38 MAPK but not ERK1/2 ([Fig. 5](#fig0025){ref-type="fig"}B). Because the expression of ADAMTS-4 is induced during monocyte--macrophage differentiation ([@bib0195]), the effect of these knockdown on the constitutive expression of ADAMTS-4 in macrophages, driven by the differentiation process, was also determined. This was inhibited by knockdown of only p38 MAPK but not Smad-2 plus -3, ERK1/2 or c-Jun ([Fig. 6](#fig0030){ref-type="fig"}).

4. Discussion {#sec0070}
=============

Several members of the ADAMTS family have been linked with inflammation but their role in this and in pathophysiological inflammatory states including atherosclerosis is only beginning to be researched ([@bib0140]). Although the exact role of the ADAMTS proteases in atherosclerosis remains unclear it is thought that the ability of ADAMTS-1 and -4 to cleave versican, the primary proteoglycan component of the vasculature, is likely to be central to any hypothesised role in the disease ([@bib0140; @bib0210]). The production and secretion of proteases by smooth muscle cells and by macrophages is a key regulatory action during atherosclerosis ([@bib0015]). The vulnerability of the atherosclerotic plaque is determined by the balance between the synthesis and the degradation of the ECM. This degradation is achieved through the action of MMPs and other proteases such as the ADAMTS proteases, which cleave the collagens and proteoglycans of the ECM ([@bib0040; @bib0120]).

We demonstrate for the first time that ADAMTS-4 mRNA and protein expression is inhibited by the anti-atherogenic cytokine TGF-β in THP-1 macrophages and HMDMs ([Figs. 1 and 2](#fig0005 fig0010){ref-type="fig"}). The response is also conserved in hepatocytes ([Fig. 3](#fig0015){ref-type="fig"}). This novel finding is consistent with the work of [@bib0195] who found that ADAMTS-4 mRNA expression can be up-regulated by the pro-inflammatory cytokines IFN-γ and TNF-α in THP-1 macrophages. In addition to this, TGF-β has been demonstrated to inhibit the expression of a number of MMPs, including MMP-1 ([@bib0200]), MMP-3 ([@bib0075]) and MMP-9 ([@bib0125]). In our studies, down-regulation of ADAMTS-4 mRNA expression by TGF-β was observed within 1 h and continued up to 24 h of treatment with this cytokine ([Fig. 1](#fig0005){ref-type="fig"}).

In addition to characterising the response of ADAMTS-4 to TGF-β, we also identify the regulatory region of the ADAMTS-4 promoter involved in this response. We show here that ADAMTS-4 promoter activity was suppressed by TGF-β treatment ([Fig. 4](#fig0020){ref-type="fig"}). Transient transfection of ADAMTS-4 promoter deletion constructs demonstrates an involvement of the −100/+10 region in the negative regulation of the ADAMTS-4 promoter by TGF-β ([Fig. 4](#fig0020){ref-type="fig"}). Of the ADAMTS proteases, only the promoters of ADAMTS-4 and ADAMTS-5 have been characterised ([@bib0110; @bib0175; @bib0180]). [@bib0110] have identified the −383 to +10 sequence of the ADAMTS-4 promoter as the region required for full promoter activity. In addition, analysis of the promoter activity of various deletion constructs suggested that the region between −726 and −384 was likely to contain silencer elements ([@bib0110]).

We also show that the Smad pathway is required in the action of TGF-β on ADAMTS-4 expression. The Smads are the classical transducers of the TGF-β signal ([@bib0135]) and Smad-2, -3 and -4 are expressed in macrophages and foam cells of atherosclerotic lesions ([@bib0070]). Following siRNA-mediated knockdown of Smad-2 plus -3, the TGF-β-mediated inhibition of ADAMTS-4 mRNA expression was no longer significant ([Fig. 5](#fig0025){ref-type="fig"}). Smads have been implicated in the repression of a number of genes by TGF-β including monocyte chemoattractant protein-1, involved in the recruitment of monocytes in inflammatory vascular disease states ([@bib0020]), and the scavenger receptor CD36, which has been shown to be regulated by a reduction in peroxisome proliferator-activated receptor-γ activity mediated by TGF-β through Smad-3 and the activator protein-1 (AP-1) family ([@bib0035]). In addition, our data suggest an involvement of MAPKs as the TGF-β-mediated inhibition of ADAMTS-4 was no longer significant following siRNA-mediated knockdown of p38 MAPK and c-Jun (a key downstream target for JNK pathway) ([Fig. 5](#fig0025){ref-type="fig"}). In contrast, the ERK pathway was not involved ([Fig. 5](#fig0025){ref-type="fig"}). TGF-β is able to activate the MAPK pathways ([@bib0165]) but whether this acts independently or in conjunction with the classical Smad pathway is unclear. Smads have been shown to interact with the c-Jun and c-fos proteins, components of the AP-1 transcription factor complex ([@bib0190]), and the TGF-β-mediated inhibition of MMP-1 expression has been shown to be dependent on the interaction between Smads and the AP-1 site present within the MMP-1 promoter ([@bib0045]).

Several cytokines are present in atherosclerotic lesions and the action of combinations of cytokines on gene expression and cellular changes is likely to be more profound than that produced by a single cytokine. For example, our previous studies have shown that there is a synergism between IFN-γ and TNF-α in the regulation of macrophage lipoprotein lipase gene expression ([@bib0170]). On the other hand, IFN-γ antagonises the action of TGF-β ([@bib0185]). Future studies should therefore investigate the action of combinations of cytokines on ADAMTS-4 expression.

In conclusion, we have shown that ADAMTS-4 is negatively regulated by TGF-β in human macrophages and that this regulation requires Smads, p38 MAPK and c-Jun. We have identified the minimal regulatory promoter region involved in this response. These findings are likely to be important for atherosclerosis given the potent anti-atherogenic action of TGF-β, as demonstrated by numerous studies *in vitro* and *in vivo*, and the demonstrated crucial role of proteases in the regulation of plaque stability. It is therefore essential that the role of ADAMTS-4 in the regulation of atherosclerosis in mouse model systems is determined.
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![TGF-β inhibits ADAMTS-4 mRNA expression in THP-1 macrophages. THP-1 macrophages were treated for 24 h with the indicated concentration of TGF-β (A) or with 30 ng/ml of this cytokine for the time points shown (B). Total RNA was isolated and subjected to RT-qPCR. The Ct method was used for analysis and the values for ADAMTS-4 were normalised to the control gene GAPDH (A) or RPL13A (B). The data shows the expression relative to the 0 ng/ml (A) or 0 h (B) (arbitrarily assigned as 1) (mean ± SD from three independent experiments). Asterisks indicate significant down-regulation of ADAMTS-4 mRNA expression (\**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001).](gr1){#fig0005}

![TGF-β inhibits ADAMTS-4 protein expression in macrophages. THP-1 macrophages (A) or HMDMs (B) were either left untreated (UT) or incubated with 30 ng/ml TGF-β for the time points indicated. An equal amount of the protein extract was subjected to Western blot analysis using antisera against ADAMTS-4 and the control β-actin, as shown. The relative ADAMTS-4 expression normalised to β-actin, as determined by densitometric analysis, from three independent experiments is shown (mean ± SD) with the values from untreated cells arbitrarily assigned as 1 (\**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001).](gr2){#fig0010}

![TGF-β inhibits ADAMTS-4 protein expression in Hep3B cells. The cells were either left untreated (UT) or incubated with TGF-β for 48 h. Equal amounts of protein were subjected to Western blot analysis using antisera against ADAMTS-4 and the control β-actin, as indicated. The relative ADAMTS-4 expression normalised to β-actin, as determined by densitometric analysis, from three independent experiments is shown (mean ± SD) with the value from untreated cells arbitrarily assigned as 1 (\**P* \< 0.05).](gr3){#fig0015}

![TGF-β inhibits ADAMTS-4 promoter activity. (A) Schematic representation of the different ADAMTS-4 promoter-luciferase DNA constructs used. Hep3B cells (B) and U937 monocytes (C) were transfected with the ADAMTS-4 promoter-luciferase DNA constructs using Superfect™. The cells were either left untreated or treated overnight with 30 ng/ml TGF-β (1 μM PMA was also included for U937 only to initiate differentiation) and cell lysates were measured for luciferase activity. Data shown is the ratio of luciferase activity:protein concentration expressed as the fold change in activity relative to the equivalent untreated sample (arbitrarily assigned as 1) and is representative of three independent experiments (NS, not significant, \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001).](gr4){#fig0020}

![The effect of siRNA-mediated knockdown of key components of the TGF-β signalling pathway on the inhibition of ADAMTS-4 expression by this cytokine. THP-1 monocytes were transfected with validated siRNA against Smad-2 and -3, ERK 1/2, c-Jun or p38 MAPK as shown. Cells were incubated with siRNA for 24 h before differentiation for 24 h with PMA and subsequently being either left untreated (UT) or stimulated with 30 ng/ml TGF-β for 24 h. Total RNA and protein was then purified. (A) siRNA-mediated knockdown was verified by Western blot analysis using antisera against total Smad-2 and -3, ERK 1/2, c-Jun, p38 MAPK (p38) and β-actin, as indicated. The image shown is representative of three independent experiments. The histogram shows relative expression (mean ± SD) of each protein normalised to β-actin, as determined by densitometric analysis, with the values from GAPDH siRNA-transfected cells being arbitrarily assigned as 1 (\**P* \< 0.05, \*\**P* \< 0.01). (B) Total RNA was subjected to RT-qPCR and the ADAMTS-4 expression was normalised to the control gene RPL13A and presented as the fold change relative to the untreated sample for each siRNA, which was arbitrarily assigned as 1. The data shown is representative of three independent experiments (NS, not significant, \*\**P* \< 0.01).](gr5){#fig0025}

![The effect of siRNA-mediated knockdown on the constitutive expression of ADAMTS-4 in THP-1 macrophages. The experiments were carried out as [Fig. 5](#fig0025){ref-type="fig"} and the relative constitutive mRNA expression of ADAMTS-4 (i.e. in the absence of TGF-β), normalised to the control gene RPL13A and presented as a fold change relative to the GAPDH-transfected sample (assigned as 1) from three independent experiments, is shown (NS, not significant, \**P* \< 0.05).](gr6){#fig0030}
